BioSpace News Archive

CG Oncology, Inc. announced today that it has entered into a clinical trial collaboration agreement to evaluate the combination of CG Oncology’s investigational oncolytic immunotherapy CG0070, with Roche’s atezolizumab, an anti-PD-L1 (programmed death-ligand 1) therapy.

Hexagon Bio today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.

Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at the 2021 Cantor Virtual Global Healthcare Conference.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that the TSX Venture Exchange has accepted the Company’s Notice of Intention to implement a normal course issuer bid.

NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has issued a local coverage determination for the use of QSant™.

Sirnaomics, Inc. today announced that it will be presenting positive results from a Phase 2a clinical study of the company’s lead drug candidate at the 2021 TIDES USA event.

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today introduced the KnowU™, a new portable medical-grade glucose monitoring device that utilizes Bio-RFID™, Know Labs’ non-invasive diagnostic technology.

Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced that the Company is scheduled to present virtually at the 2021 Cantor Virtual Global Healthcare Conference.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression.

Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will present at the prestigious Forsyth dentech 2021 oral health technology conference on Thursday, September 23, 2021.